Last reviewed · How we verify
Pyrotinib, Trastuzumab, Docetaxel
Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while Trastuzumab is a monoclonal antibody targeting the HER2 protein, and Docetaxel is a taxane inhibitor of microtubule assembly.
Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while Trastuzumab is a monoclonal antibody targeting the HER2 protein, and Docetaxel is a taxane inhibitor of microtubule assembly. Used for Advanced or metastatic breast cancer with HER2 overexpression, Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression.
At a glance
| Generic name | Pyrotinib, Trastuzumab, Docetaxel |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Tyrosine kinase inhibitor, Monoclonal antibody, Taxane |
| Target | HER2/neu receptor, HER2 protein, Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pyrotinib works by inhibiting the tyrosine kinase activity of the HER2/neu receptor, which is overexpressed in certain types of cancer. Trastuzumab binds to the HER2 protein on the surface of cancer cells, marking them for destruction by the immune system. Docetaxel interferes with the normal function of microtubules in cells, which are necessary for cell division and growth.
Approved indications
- Advanced or metastatic breast cancer with HER2 overexpression
- Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- ctDNA in HER2+ EBC Neoadjuvant Treatment (PHASE2)
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer (PHASE2)
- Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer (PHASE2, PHASE3)
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model (PHASE3)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer (PHASE3)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: